from the promptly evolving subject of oncology investigation, exact and effective mutation screening is critical for acquiring targeted therapies. The KRAS solutions System plays a pivotal purpose in this landscape by featuring in depth options for KRAS mutation profiling and Evaluation. KRAS mutations, present in roughly 95% of RAS-associated onco